Details for Patent: 7,893,074

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 7,893,074 protect, and when does it expire?

Patent 7,893,074 protects ZYKADIA and is included in two NDAs.

This patent has ninety-two patent family members in thirty-five countries.

Summary for Patent: 7,893,074

Title:	2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Abstract:	Novel pyrimidine derivatives of formula I ##STR00001## to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
Inventor(s):	Garcia-Echeverria; Carlos (Basel, CH), Kanazawa; Takanori (Tsukuba, JP), Kawahara; Eiji (Tsukuba, JP), Masuya; Keiichi (Tsukuba, JP), Matsuura; Naoko (Tsukuba, JP), Miyake; Takahiro (Tsukuba, JP), Ohmori; Osamu (Tsukuba, JP), Umemura; Ichiro (Tsukuba, JP), Steensma; Ruo (La Jolla, CA), Chopiuk; Greg (San Diego, CA), Jiang; Jiqing (San Diego, CA), Wan; Yongqin (Irvine, CA), Ding; Qiang (San Diego, CA), Zhang; Qiong (San Diego, CA), Gray; Nathanael Schiander (San Diego, CA), Karanewsky; Donald (Escondido, CA)
Assignee:	Novartis AG (Basel, CH) IRM LLC (Hamilton, BM)
Application Number:	10/568,367
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent 7,893,074

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		DISCN	Yes	No	See Plans and Pricing	See Plans and Pricing	Y	Y			See Plans and Pricing
Novartis	ZYKADIA	ceritinib	TABLET;ORAL	211225-001	Mar 18, 2019		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing	Y	Y			See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 7,893,074

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0319227.5	Aug 15, 2003
United Kingdom	0322370.8	Sep 24, 2003

PCT Information
PCT Filed	August 13, 2004	PCT Application Number:	PCT/EP2004/009099
PCT Publication Date:	February 24, 2005	PCT Publication Number:	WO2005/016894

International Family Members for US Patent 7,893,074

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	045458	See Plans and Pricing
Argentina	107965	See Plans and Pricing
Argentina	114354	See Plans and Pricing
Austria	497495	See Plans and Pricing
Austria	542801	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.